, while the frequency of alleles G of NKG2D9 and A of NKG2D10 was greater in patients without deformities (Pc 5 0Á03, OR 5 0Á41, 95% CI 5 0Á17-0Á91 and Pc 5 0Á04, OR 5 0Á41, 95% CI 5 0Á16-0Á96). Similar trends of association were observed with deforming phenotype of RA in female patients and deforming young onset RA subgroups. Haplotype analysis revealed that the frequency of haplotype G-C-A-G-A-T-C-C was higher in patients than in controls (12 versus 8%, P 5 0Á04, OR 5 1Á61, 95% CI 5 1Á01-2Á55), suggesting that it may predispose to RA. Our study suggests that the NKG2D gene polymorphisms may modify the risk of development and severity of RA.
Introduction
Rheumatoid arthritis (RA), a systemic autoimmune disease, is characterized by irreversible joint damage and deformities. It affects 0Á5-1Á0% of adults in developed countries [1] . Synovial inflammation and hyperplasia, autoantibody production, cartilage and bone destruction over time characterize RA. The accompanying disabilities in RA impact significantly upon quality of life and socioeconomic status of the patient, the family and society at large [2] . The most significant risk factors for RA include female gender, advanced age and a family history of such disorders. The presence of familial tendency suggests a genetic predisposition to the development of RA. Genetic predisposition is thought to account for approximately one-half to two-thirds of the risk of developing RA [3] . The precise mechanism through which genetic factors act is still unclear. It is likely to be triggered by complex and stochastic interactions between genetic and environmental factors [2] .
Human and mouse natural killer (NK) cells express both activating and inhibitory cell surface receptors. Fine-tuning of immune surveillance (activated or quiescent state of NK cells) involves the integration of both activating and inhibitory receptor signalling [4] . Among many NK cell receptors, the most studied receptors are the killer-cell immunoglobulin-like receptors (KIR). Several polymorphisms in the KIR genes have been identified, and the association of KIR genes with RA have been reported in Caucasian [5] , Polish [6] , Taiwanese [7] , Mexican [8] and Iranian [9] populations. In a case-control study involving 100 North Indian subjects with RA the presence of KIRDS1 and KIRDS2 increased the risk of RA, whereas KIRDL1, KIRDL2 and KIRDL3 were protective. The presence of KIRDS1 and KIRDS3 increased the risk of extra-articular complications and deforming disease in patients with RA [10] . KIR gene polymorphisms are reported to influence disease severity and treatment response to methotrexate [11, 12] .
In humans, the NK gene complex on chromosome 12p12-p13 harbours 19 genes that encode for C-type lectins NKG2 and CD94. NKG2D lies amid this cluster of genes, referred to as 'NK complex' (NKC). Several genes expressed by NK cells, including KLRD1 (CD94) on the centromeric side and KLRC4 (NKG2F), KLRC3 (NKG2E), KLRC2 (NKG2C) and KLRC1 (NKG2A) on the telomeric side, are located within this complex. NKG2D (KLRK1) encoded by killer cell lectin-like receptor subfamily K is an activatory C-type lectin receptor on NK cells, gamma delta T (gd T) cells, CD8 [13] .
Most of the published literature related to NKG2D in autoimmune diseases concerns MIC molecules, MICA and MICB. Genetic analyses have revealed a predisposition to develop RA in Tunisian patients bearing the A/A genotype of the single nucleotide polymorphism (SNP) MICA-250. The same study also revealed increased risk of seropositive RA in those individuals carrying the G allele and G/G genotype of MICA-250 SNP and the (val) allele and (val/ val) genotype of MICAmet129val SNP [14] . An autoimmune response is triggered if MIC molecules are induced non-specifically by an inflammatory process or expressed inappropriately on the cells in predisposed individuals [15] . Dysregulated receptor/ligand expression was first reported in RA for NKG2D/MICA [16] . High levels of interleukin (IL)215 and tumour necrosis factor (TNF)-a found in the serum and inflamed joints of RA patients induce expansion of autoreactive CD4 1 CD28
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1 cells in peripheral blood and synovial tissue [16] . MICA and MICB up-regulated in RA synoviocytes are capable of activating these autoreactive autologous T cells in an NKG2D-dependent manner [17] . While an abundance of soluble MICA (sMICA) has been found in the serum and synovial fluid of RA patients, it is unable to down-regulate the activating NKG2D receptors on NK cells due to massive NKG2D up-regulation driven by elevated levels of IL-15 and TNF-a. These reports suggest that dysregulation of NKG2D and abnormal expression of MIC in the local tissue environment can cause autoreactive T cell stimulation, contributing to the pathogenesis of RA [15] . There is a paucity of data on the role of NKG2D polymorphism on disease susceptibility, severity and outcomes in RA, with the exception of one study from Korea [18] . Hence, this study was carried out to identify the contribution of polymorphisms in NKG2D gene towards risk of the development of RA and their influence on disease characteristics and response to methotrexate-based synthetic diseasemodifying anti-rheumatic drug (DMARD) therapy in South Indian Tamil patients.
Methods
Study design
This was a case-control immunogenetic study conducted at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, a major tertiary care referral center in South India.
Study subjects
Ethnic Tamil South Indian patients fulfilling the 2010 modified American College of Rheumatology Criteria (ACR) [19] for rheumatoid arthritis were recruited for the study. A total of 236 patients (215 females and 21 males) were enrolled. Patients with inactive disease or other comorbid conditions were excluded. The mean age of patients at enrolment was 40Á9 6 11Á1 years (range 5 18-72 years) and age of onset was 37Á3 6 11Á6 years (range 5 17-72 years). Their clinical characteristics are presented in Table 1 . All patients received methotrexate (MTX) as initial therapy up to a maximum of 25 mg per week. In case of inadequate response, sulphasalazine (SSZ) up to 2 g per day and hydroxychloroquine (HCQ) up to 400 mg per day, with or without low-dose prednisolone (< 7Á5 mg per day) was added. Treatment response was assessed using European League Against Rheumatism (EULAR) response criteria [20] at the end of 6 months or after 8 continuous weeks of a stable combination of DMARD therapy, whichever was later. Clinical characteristics assessed were age of onset (young onset RA, or YORA -onset before 55 years); presence or absence of deformities; and presence or absence of extra-articular features related to RA (rheumatoid nodules, sicca symptoms, lung involvement, neuropathy and vasculitis).
A total of 187 (157 females and 30 males) unrelated age-, sex-and ethnicity-matched healthy individuals without family history of autoimmune disorders were included as healthy controls (HC). Written informed consent was obtained from all study participants before enrolment. The study was reviewed and approved by the Institutional Ethics Committee.
Autoantibody measurement
Immunoglobulin (Ig)M rheumatoid factor (RF) in the serum of patients was measured by Nephelometry (Seimens Health Care, Marburg, Germany N Prospec V R ; Dade Behring, Germany) using kits supplied by Siemens Healthcare Diagnostics Inc. (Marburg, Germany). RF titres above 10 IU/ml were considered positive. ACPA status was determined by sandwich enzyme-linked immunosorbent assay (ELISA) method using a second-generation commercial ELISA kit (Biosystems, Barcelona, Spain). Patients with values of ACPA above 15 IU/ml were labelled as ACPApositive.
DNA extraction
Genomic DNA from patients and controls was extracted from peripheral blood leucocytes using a standard protocol. The quality and quantity of DNA were analysed by spectrophotometry (Nanodrop, ThermoScientific, Fremont, CA, USA).
NKG2D and NKG2A genotyping
We evaluated seven single nucleotide polymorphisms (SNPs) in NKG2D gene (rs1049174: NKC-3, rs2255336:
NKC-4, rs2617160: NKC-7, rs2246809: NKC-9, rs2617169: NKC-10 and rs2617170: NKC-11, rs2617171: NKC-12) and one SNP in NKG2A gene (rs1983526: NKC-17) using a predesigned TaqMan 5' nuclease assay (Applied Biosystems, Foster City, CA, USA) with allele-specific fluorogenic oligonucleotide probes allowing discrimination of each pair of alleles under investigation. Briefly, 50 ng of DNA was amplified in a 10 ml reaction containing 5 ml of TaqMan genotyping master mix, 0Á25 ml of 340 allelic discrimination mix and 3Á75 ml of DNase and RNase free water using the following polymerase chain reaction (PCR) cycling conditions: preread at 608C for 1 min, hold at 508C for 2 min, 958C for 10 min followed by 40 cycles of 958C for 15 s, 608C for 1 min and postread at 608C for 1 min for all the above polymorphisms of NK receptors except NKG2D12. PCR conditions for NKG2D12 was preread at 608C for 1 min, hold at 508C for 2 min, 958C for 10 min followed by 40 cycles of 958C for 15 s, 608C for 1 min 30 s and postread at 608C for 1 min [21] . PCR plates were run and read in the ABI StepOne Plus TM Sequence Detection System (Applied Biosystems). Results were analysed using allelic discrimination software.
Statistical analysis
Sample size was calculated using the CaTS power calculator for genetic studies [22] , taking into account the described minor allele frequency with significance level of 0Á05 and power of 0Á8. Allele and genotype frequencies of the studied SNPs were compared between patients and controls using the v 2 test with Yates' correction. P-values less than 0Á05
were considered significant. Both odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the relative risk conferred by a specific allele or genotype. Gender, age of onset, disease activity, erosive/deforming disease, extra-articular manifestations, autoantibody (RF, ACPA) positivity and response to DMARD therapy were the characteristics included in the analysis. 
Results
Distribution of NK receptor genotypes/alleles
Eight different SNPs clustered in the NK complex (rs1049174, rs2255336, rs2617160, rs2246809, rs2617169, rs2617170, rs2617171 and rs1983526) were genotyped in 236 patients and 187 controls. The genotype/allele frequency did not differ between patients and controls for all the eight different polymorphisms analysed in this study. However, the CC genotype of NKC-12 (rs2617171) (22 versus 15%, Pc 5 0Á07, OR 5 1Á64, 95% CI 5 0Á97-2Á84) and the CC genotype of NKC-17 (rs1983526) (38 versus 29%, Pc 5 0Á06, OR 5 1Á52, 95% CI 5 0Á97-2Á34) were higher in patients compared to controls, albeit not to a level of statistical significance, suggesting a possible role in susceptibility to RA ( Table 2) .
Association of NK receptor polymorphism with clinical phenotypes
Analysis of the association of the NK receptor polymorphisms with clinical characteristics (namely age at onset, presence or absence of deformities, extra-articular manifestations and autoantibody status) was performed. We observed that the frequency of GG genotype and G allele of NK9 (rs2246809) (91 versus 80%, Pc 5 0Á04, OR 5 0Á41, 95% CI 5 0Á16-0Á96 and 95 versus 89%, Pc 5 0Á03, OR 5 0Á41, 95% CI 5 0Á17-0Á91, respectively) and AA genotype and A allele of NK10 (rs2617169) (92 versus 81%, Pc 5 0Á04, OR 5 0Á40, 95% CI 5 0Á15-0Á97 and 96 versus 90% Pc 5 0Á04, OR 5 0Á41, 95% CI 5 0Á16-0Á95, respectively) was significantly higher in individuals without deformities compared to those with deformities. We observed that the frequencies of A allele of NK9 (rs2246809) and the T allele of NK10 (rs2617169), respectively, were significantly higher in patients with deformities (11 versus 5%, Pc 5 0Á03, OR 5 2Á44, 95% CI 5 1Á09-5Á98 and 10 versus 4%, Pc 5 0Á04, OR5 2Á45, 95% CI 5 1Á05-6Á39). A similar trend of association was observed in female patients and those with YORA having deformities ( Table 3) .
Association of NK receptor polymorphism with treatment response
Polymorphisms in the NK receptor complex were not found to be associated with response to treatment with methotrexate-based synthetic DMARD therapy.
Association of NK receptor haplotypes with RA susceptibility
Linkage analysis was performed for the eight bi-allelic SNPs of various genes in the NK cell receptor complex, including NKG2D3, NKG2D4, NKG2D7, NKG2D9, NKG2D10, NKG2D11, NKG2D12 and NKG2A17 on chromosome 12. Haplotypes were constructed for 236 patients and 187 controls. We observed that the frequency of haplotype G-C-A-G-A-T-C-C was higher in patients than in controls (12 versus 8%, P 5 0Á04, OR 5 1Á61, 95% CI 5 1Á01-2Á55) (Fig. 1, Table 4 ), suggesting that the presence of this haplotype predisposed to the development of RA.
Discussion
NKG2D dysregulation and abnormal MIC expression can cause autoreactive T cell stimulation and promote pathogenic process in RA [15] . It is likely that polymorphisms in NK cell receptors such as NKG2D may play a major role in modulating NK cell activation. To address this issue, eight different SNPs in the NK gene complex (rs1049174, rs2255336, rs2617160, rs2246809, rs2617169, rs2617170, rs2617171 and rs1983526) were genotyped in RA patients and healthy controls. We observed that the genotype/allele frequency did not differ between patients and controls for all the eight polymorphisms analysed. However, the G-C-A-G-A-T-C-C haplotype was more frequent in patients with RA than in healthy controls, suggesting that NKD2D may play a role in predisposing to development of RA.
In our study, we observed that the frequency of allele A (rs2246809) and T (rs2617169) was significantly higher in patients with deformities, while that of the other alleles G (rs2246809) and A (rs2617169) was higher in patients without deformities. A similar trend of association was observed with the deforming disease in female patients and in those with young age of onset. However, NKG2D polymorphisms did not appear to influence the phenotype related to RF and ACPA autoantibodies.
Park et al., from Korea, reported that the NKG2D (rs225536) thr/thr genotype conferred risk of developing RA. They also reported that the increased risk was noted in individuals with NKG2C (rs1141715) ser/ser and NKG2D (rs225536) thr/thr genotypes and that the presence of these two polymorphisms together increase RA risk by 12-fold [18] . No association was noted with other variants of NKG2D (rs1049174 and rs1049172). Contrary to their report that NK cell receptor polymorphism did not affect the antibody production and joint erosions, we observed that NKG2D polymorphisms were associated with the development of deformities in South Indian Tamil patients. The differences in our findings could be explained by the larger number of SNPs studied by us in a different population. Therefore, it is quite possible that different polymorphisms of NKG2D influence different disease characteristics in RA.
Our findings compare favourably with studies in other autoimmune disorders, such as diabetes mellitus, paediatric inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE). In these diseases, NKG2D has been reported to play a major role in disease severity and progression by altering the distribution and signal strength of receptors [23] [24] [25] [26] . Non-depleting anti-NKG2D treatment during the prediabetic stage of non-obese diabetic (NOD) mice prevented the development of diabetes by impairing suggesting that NKG2D is essential for disease progression [23] . In paediatric IBD, prophylactic anti-NKG2D therapy attenuated the development of colitis. It also reduced severity when administered to animals with mild but not severe colitis [24, 25] . In the case of systemic autoimmune diseases such as SLE, the NKG2D rs2255336 (NKC-4) ala/ala genotype was found to have a high prevalence in German and Spanish patients [26] , while the Thr allele (rs2255336) was reported to be protective in SLE patients from Poland [27] . Kabalak et al. hypothesized that this SNP does not affect the cell surface expression of NKG2D but changes the binding affinity to its adapter DAP10, thus altering the signal strength. In the presence of the ala/ala genotype of NKC-4, activation of CD4 1 CD28 -NKG2D 1 cells is reduced, leading to severe disease in SLE [26] . Similar mechanisms may be operative in RA, responsible for early onset of the disease and a severe phenotype with deformities reported by us.
Hayashi et al. reported the presence of two different haplotype blocks in the NK gene complex. Within these two blocks, allele combinations had either weak cytotoxic activity or high NK activity, which predisposed these patients to develop malignancy differentially [21] . In our study, we identified the G-C-A-G-A-T-C-C haplotype as a possible risk haplotype for RA. The alleles of this haplotype were found to be associated with high NK cell activity (HNK) in the study referred to above. Assessment of the degree of cytotoxic activity exhibited by this haplotype in patients with rheumatoid arthritis could form the basis of future investigation.
To conclude, our study shows that G-C-A-G-A-T-C-C haplotype of the NKG2D gene may predispose to RA. In addition, NK cell receptor polymorphisms may also play a role in influencing disease expression, with certain variants causing severe deforming disease. Given the reported abundance of TNF and IL-15 in RA synovium and their ability to activate autoreactive autologous T cells in an NKG2D-dependent manner, it is plausible that polymorphisms in MICA and NKG2D influence the threshold of effector cell activation in autoimmune disorders such as RA, leading to a poor outcome of the disease [16] . Further functional studies are required to understand the underlying cellular interactions/mechanisms influenced by NK receptor polymorphisms in modifying the phenotype of RA.
Key messages
Individual NKG2D receptor polymorphisms are not risk factors for RA. The G-C-A-G-A-T-C-C haplotype of NKG2D increases the risk for RA. Polymorphisms in NKC-9 and NKC-10 are risk modifiers, and may be responsible for a severe disease phenotype of RA.
